<DOC>
	<DOCNO>NCT03011749</DOCNO>
	<brief_summary>The aim study investigate whether positron emission tomography ( PET ) use tracer 18F-Fluorothymidine ( FLT ) provide information proliferative activity bone marrow patient receive Radium 223 therapy potentially predictive marker hematological toxicity</brief_summary>
	<brief_title>Value FLT PET/CT Radium-223 Therapy mCRPC Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Metastatic castration resistant prostate cancer Eligible Radium223 therapy Informed consent Inability understand study protocol Extensive metastatic involvement axial skeleton ( `` superscan '' bone scintigraphy )</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Radium-223 therapy</keyword>
</DOC>